非转移性去势抵抗性前列腺癌-话题@MedSci

#非转移性去势抵抗性前列腺癌#

9篇内容 | 1374人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2221638, encodeId=fae4222163897, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a> <a href='/topic/show?id=02553650509' target=_blank style='color:#2F92EE;'>#卡巴他赛#</a> <a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=Eur Urol Oncol：比较2周1次与3周1次卡巴他赛给药方案对转移性去势抵抗性前列腺癌老年患者疼痛管理及生活质量的影响, objectType=article, longId=839874, objectId=bd168398e430, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240821/1724204367786_92910.png, objectUrl=/article/show_article.do?id=bd168398e430, replyNumber=0, likeNumber=51, createdTime=2024-08-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bd168398e430, moduleTitle=Eur Urol Oncol：比较2周1次与3周1次卡巴他赛给药方案对转移性去势抵抗性前列腺癌老年患者疼痛管理及生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd168398e430)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197218, encodeId=7bfe219e2181d, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a> <a href='/topic/show?id=e92b10490053' target=_blank style='color:#2F92EE;'>#阿贝西利#</a> <a href='/topic/show?id=41fb11313381' target=_blank style='color:#2F92EE;'>#临床活性研究#</a>, objectTitle=CLIN CANCER RES：阿贝西利在转移性去势抵抗性前列腺癌患者中的临床活性研究（CYCLONE 1研究结果）, objectType=article, longId=820544, objectId=bfd68205442b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240406/1712410284330_6145188.png, objectUrl=/article/show_article.do?id=bfd68205442b, replyNumber=0, likeNumber=96, createdTime=2024-04-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bfd68205442b, moduleTitle=CLIN CANCER RES：阿贝西利在转移性去势抵抗性前列腺癌患者中的临床活性研究（CYCLONE 1研究结果）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfd68205442b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1459345, encodeId=6ffd14593456c, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, objectType=article, longId=215209, objectId=93d5215209e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93d5215209e6, replyNumber=0, likeNumber=72, createdTime=2021-08-04, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93d5215209e6, moduleTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93d5215209e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459344, encodeId=3143145934455, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, objectType=article, longId=215061, objectId=7b66215061fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b66215061fc, replyNumber=0, likeNumber=0, createdTime=2021-07-31, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b66215061fc, moduleTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b66215061fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459343, encodeId=33df14593431e, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析, objectType=article, longId=207265, objectId=388d20e265f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=388d20e265f5, replyNumber=0, likeNumber=80, createdTime=2021-02-20, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=388d20e265f5, moduleTitle=ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=388d20e265f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459342, encodeId=cd1f14593429f, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=203137, objectId=f21a20313e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21a20313e8c, replyNumber=0, likeNumber=114, createdTime=2020-11-10, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21a20313e8c, moduleTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21a20313e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459341, encodeId=6cf6145934138, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析, objectType=article, longId=200657, objectId=46a120065e1f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a120065e1f, replyNumber=0, likeNumber=82, createdTime=2020-09-15, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a120065e1f, moduleTitle=Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46a120065e1f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459340, encodeId=f3ea1459340c4, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, objectType=article, longId=190970, objectId=6cd81909e0c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cd81909e0c0, replyNumber=0, likeNumber=95, createdTime=2020-03-29, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cd81909e0c0, moduleTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cd81909e0c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459339, encodeId=c1fd1459339df, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=162125, objectId=bf0c162125cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf0c162125cc, replyNumber=0, likeNumber=77, createdTime=2019-03-13, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf0c162125cc, moduleTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf0c162125cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459338, encodeId=3d411459338b1, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成, objectType=article, longId=161512, objectId=f0b416151215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b416151215, replyNumber=0, likeNumber=104, createdTime=2019-03-03, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b416151215, moduleTitle=Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b416151215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459337, encodeId=8861145933e4b, content=<a href='/topic/show?id=3fc49969667' target=_blank style='color:#2F92EE;'>#非转移性去势抵抗性前列腺癌#</a>, objectTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, objectType=article, longId=160341, objectId=61af160341ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61af160341ee, replyNumber=0, likeNumber=90, createdTime=2019-02-19, rootId=0, userName=tonychen23, userId=e0a76134556, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61af160341ee, moduleTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61af160341ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非转移性去势抵抗性前列腺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#健康相关生活质量# #卡巴他赛# #非转移性去势抵抗性前列腺癌#

Eur Urol Oncol：比较2周1次与3周1次卡巴他赛给药方案对转移性去势抵抗性前列腺癌老年患者疼痛管理及生活质量的影响

2024-08-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌# #阿贝西利# #临床活性研究#

CLIN CANCER RES：阿贝西利在转移性去势抵抗性前列腺癌患者中的临床活性研究（CYCLONE 1研究结果）

2024-04-07发表于上海

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量

2021-08-04

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？

2021-07-31

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析

2021-02-20

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌

2020-11-10

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析

2020-09-15

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！

2020-03-29

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌

2019-03-13

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成

2019-03-03

tonychen23 (审核中...)

前往app查看评论内容

#非转移性去势抵抗性前列腺癌#

darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS

2019-02-19

科室
- - 订阅+
  - 更多科室
工具
服务